LCK (Tyrosine-protein kinase Lck) variants and mutations
LCK (also known as Tyrosine-protein kinase Lck) is a human protein-coding gene encoding a tyrosine-protein kinase protein. It phosphorylates the earliest signaling components downstream of the T-cell receptor and CD4 or CD8 coreceptors, making it essential for T-cell development and activation. Severe loss-of-function can cause combined immunodeficiency, while aberrant activity contributes to lymphoid malignancy. This analysis covers 701 LCK variants and mutations. Of these, 77% have computational variant effect predictions. Disease context includes severe combined immunodeficiency due to LCK deficiency, acute lymphoblastic leukemia, and cancer. Example LCK variants include G2W, G2A, and G2V.
Variant analysis overview
- Gene: LCK
- Protein: Tyrosine-protein kinase Lck
- UniProt accession: P06239
- Organism: Homo sapiens
- Variants analyzed: 701
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 472 unspecified-consequence records; 132 missense variants; 71 synonymous variants; 4 stop-gained variants; 14 frameshift variants; 2 in-frame deletions; 2 splice-region variants; 3 substitution
- Prediction scores: 540 variants have prediction scores (77% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: severe combined immunodeficiency due to LCK deficiency, acute lymphoblastic leukemia, cancer, chronic myelogenous leukemia, BCR-ABL1 positive, renal cell carcinoma, severe combined immunodeficiency, soft tissue sarcoma, sarcoma, neoplasm, combined immunodeficiency, HIV infectious disease, lymphoid leukemia.
Protein structure and variant hotspots
- Protein features: 3 domains; 2 binding sites; 7 post-translational modification sites.
- Structural context: 487 variants have structural context.
- PTM context: 6 variants overlap post-translational modification sites.
- Experimental data: 58 protein positions have experimental scores. Source: LCK SH3 domain domainome 1.0.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable LCK variants
Examples include G2W, G2A, G2V, G2E, G2G, C3S, C3F, C3C. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- G2W (p.Gly2Trp), gnomAD 1-32274201-G-T, CADD 7.39
- G2A (p.Gly2Ala), rs1280171764, gnomAD 1-32274202-G-C, CADD 2.54
- G2V (p.Gly2Val), rs1280171764, gnomAD 1-32274202-G-T, CADD 2.42
- G2E (p.Gly2Glu), gnomAD 1-32274202-G-A, CADD 2.94
- G2G (p.Gly2Gly), gnomAD 1-32274203-G-A, CADD 5.80
- C3S (p.Cys3Ser), Ensembl rs1640189479, REVEL 0.41, CADD 28.10
- C3F (p.Cys3Phe), gnomAD 1-32274337-G-T, REVEL 0.47, CADD 29.40
- C3C (p.Cys3Cys), rs1240141053, gnomAD 1-32274338-T-C, CADD 13.10
- G4R (p.Gly4Arg), gnomAD 1-32274210-G-C, CADD 0.42
- G4E (p.Gly4Glu), rs756114802, gnomAD 1-32274211-G-A, CADD 7.06
- G4G (p.Gly4Gly), gnomAD 1-32274212-A-G, CADD 5.22
- G4S (p.Gly4Ser), gnomAD 1-32274339-G-A, REVEL 0.08, CADD 13.90
- C5R (p.Cys5Arg), gnomAD rs1257794961, REVEL 0.29, CADD 25.10, Uncertain significance, not specified
- C5W (p.Cys5Trp), rs1486428010, ClinGen CA339633907, ClinVar RCV002040857, gnomAD rs1486428010, REVEL 0.23, CADD 27.60, Uncertain significance, Severe combined immunodeficiency due to LCK deficiency
- C5Y (p.Cys5Tyr), gnomAD 1-32274343-G-A, REVEL 0.26, CADD 23.10
- S6F (p.Ser6Phe), gnomAD 1-32274214-C-T, CADD 4.09
- S6S (p.Ser6Ser), gnomAD 1-32274215-T-C, CADD 3.30
- S7T (p.Ser7Thr), gnomAD 1-32274264-T-A, CADD 10.80
- S7C (p.Ser7Cys), rs1640187491, gnomAD 1-32274265-C-G, CADD 13.70
- S7L (p.Ser7Leu), gnomAD 1-32274349-C-T, REVEL 0.12, CADD 23.60
- H8N (p.His8Asn), ExAC rs763977216, gnomAD rs763977216, REVEL 0.07, CADD 16.80
- H8Y (p.His8Tyr), ExAC rs763977216, gnomAD rs763977216, REVEL 0.12, CADD 16.80
- H8H (p.His8His), rs778938809, gnomAD 1-32274218-C-T, CADD 6.41
- P9L (p.Pro9Leu), ExAC rs111771386, TOPMed rs111771386, gnomAD rs111771386, REVEL 0.12, CADD 8.56
- P9Q (p.Pro9Gln), ExAC rs111771386, TOPMed rs111771386, gnomAD rs111771386
- P9S (p.Pro9Ser), gnomAD 1-32274207-C-T, CADD 0.51
- P9T (p.Pro9Thr), gnomAD 1-32274207-C-A, CADD 0.38
- P9P (p.Pro9Pro), gnomAD 1-32274209-A-C, CADD 4.73
- E10D (p.Glu10Asp), rs2124350577, ClinGen CA339634015, ClinVar RCV001996900, Ensembl rs2124350577, REVEL 0.09, CADD 11.80, Uncertain significance, Severe combined immunodeficiency due to LCK deficiency
- E10K (p.Glu10Lys), NCI-TCGA Cosmic COSV6073, cosmic curated COSV60739, REVEL 0.09, CADD 23.00, Variant assessed as somatic; moderate impact.
- E10del (p.Glu10del), rs1244165498, gnomAD 1-32274356-GGAA-G, CADD 19.30
- E10A (p.Glu10Ala), gnomAD 1-32274358-A-C, REVEL 0.06, CADD 22.50
- D11N (p.Asp11Asn), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10028, REVEL 0.06, CADD 23.80, Variant assessed as somatic; moderate impact.
- D12A (p.Asp12Ala), TOPMed rs1640190258
- D12N (p.Asp12Asn), NCI-TCGA Cosmic COSV6074, cosmic curated COSV60740, Variant assessed as somatic; moderate impact.
- D12Y (p.Asp12Tyr), gnomAD 1-32274363-G-T, REVEL 0.20, CADD 26.60
- D12G (p.Asp12Gly), gnomAD 1-32274364-A-G, REVEL 0.14, CADD 23.00
- W13* (p.Trp13Ter), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10028, CADD 13.30, Variant assessed as somatic; high impact.
- W13R (p.Trp13Arg), rs768835510, gnomAD 1-32274234-T-C, CADD 6.96
- W13G (p.Trp13Gly), rs768835510, gnomAD 1-32274234-T-G, CADD 7.65
- W13C (p.Trp13Cys), rs1640186761, gnomAD 1-32274236-G-C, CADD 13.00
- M14L (p.Met14Leu), ExAC rs780185907, gnomAD rs780185907, REVEL 0.07, CADD 22.50, Uncertain significance, not specified
- M14I (p.Met14Ile), gnomAD 1-32274371-G-A, REVEL 0.09, CADD 17.80
- N16S (p.Asn16Ser), Ensembl rs2124350602
- N16K (p.Asn16Lys), rs1475748793, gnomAD 1-32274239-C-A, CADD 4.60
- N16D (p.Asn16Asp), gnomAD 1-32274375-A-G, REVEL 0.14, CADD 22.90
- I17M (p.Ile17Met), ExAC rs751726470, gnomAD rs751726470, REVEL 0.08, CADD 14.80
- I17V (p.Ile17Val), rs1422197069, ClinGen CA339634168, ClinVar RCV001899300, gnomAD rs1422197069, REVEL 0.06, CADD 18.90, Uncertain significance, Severe combined immunodeficiency due to LCK deficiency
- I17I (p.Ile17Ile), rs1226871403, gnomAD 1-32274206-C-T, CADD 3.03
- I17L (p.Ile17Leu), rs1398786002, gnomAD 1-32274253-GC-G, CADD 5.15
- I17R (p.Ile17Arg), gnomAD 1-32274377-CAT-C, CADD 29.60
- I17F (p.Ile17Phe), gnomAD 1-32274378-A-T, REVEL 0.08, CADD 21.30
- D18H (p.Asp18His), ExAC rs755284744, TOPMed rs755284744, gnomAD rs755284744
- D18N (p.Asp18Asn), ExAC rs755284744, TOPMed rs755284744, gnomAD rs755284744, REVEL 0.13, CADD 25.00
- D18D (p.Asp18Asp), gnomAD 1-32274269-T-C, CADD 9.45
- D18E (p.Asp18Glu), gnomAD 1-32274269-T-A, CADD 8.98
- E21K (p.Glu21Lys), gnomAD 1-32274390-G-A, REVEL 0.12, CADD 24.20
- E21D (p.Glu21Asp), gnomAD 1-32274392-G-C, REVEL 0.04, CADD 15.80
- E21E (p.Glu21Glu), gnomAD 1-32274392-G-A, CADD 9.75
- N22H (p.Asn22His), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- N22T (p.Asn22Thr), ExAC rs77219908, gnomAD rs77219908
- N22N (p.Asn22Asn), gnomAD 1-32274395-C-T, CADD 13.20
- H24H (p.His24His), rs1557582944, gnomAD 1-32274401-T-C, CADD 9.94
- Y25H (p.Tyr25His), gnomAD rs1360740802
- Y25* (p.Tyr25Ter), rs747268826, gnomAD 1-32274230-C-G, CADD 10.50
- P26A (p.Pro26Ala), NCI-TCGA Cosmic COSV6073, cosmic curated COSV60738, Variant assessed as somatic; moderate impact.
- P26S (p.Pro26Ser), rs1465519273, gnomAD 1-32274255-C-T, CADD 10.20
- P26T (p.Pro26Thr), gnomAD 1-32274255-C-A, CADD 9.56
- P26L (p.Pro26Leu), gnomAD 1-32274256-C-T, CADD 5.58
- P26P (p.Pro26Pro), gnomAD 1-32274257-C-T, CADD 5.32
- I27V (p.Ile27Val), ExAC rs748563929, TOPMed rs748563929, gnomAD rs748563929, REVEL 0.13, CADD 21.30
- I27I (p.Ile27Ile), rs1296543827, gnomAD 1-32274410-A-T, CADD 13.80
- V28L (p.Val28Leu), UniProt VAR 013463, Uncertain significance
- V28I (p.Val28Ile), rs1376659267, gnomAD 1-32274270-G-A, CADD 6.95
- V28G (p.Val28Gly), rs777201725, gnomAD 1-32274271-T-G, CADD 1.60
- V28A (p.Val28Ala), rs777201725, gnomAD 1-32274271-T-C, CADD 1.84
- V28V (p.Val28Val), rs144437329, gnomAD 1-32274413-C-T, CADD 9.10
- P29R (p.Pro29Arg), Ensembl rs1126766
- P29S (p.Pro29Ser), cosmic curated COSV10741, NCI-TCGA TCGA novel, TOPMed rs1640191298, gnomAD rs1640191298, REVEL 0.06, CADD 23.00, Variant assessed as somatic; moderate impact.
- P29A (p.Pro29Ala), gnomAD 1-32274297-C-G, CADD 10.20
- P29H (p.Pro29His), gnomAD 1-32274307-C-A, CADD 5.76
- P29L (p.Pro29Leu), gnomAD 1-32274307-C-T, CADD 6.40
- P29P (p.Pro29Pro), gnomAD 1-32274416-A-G, CADD 9.62
- L30P (p.Leu30Pro), ExAC rs749818114, TOPMed rs749818114, gnomAD rs749818114, REVEL 0.13, CADD 23.10
- L30R (p.Leu30Arg), ExAC rs749818114, TOPMed rs749818114, gnomAD rs749818114, REVEL 0.15, CADD 22.90
- L30I (p.Leu30Ile), gnomAD 1-32274285-C-A, CADD 5.22
- L30F (p.Leu30Phe), gnomAD 1-32274285-C-T, CADD 5.88
- L30L (p.Leu30Leu), rs1303366697, gnomAD 1-32274417-C-T, CADD 12.60
- D31G (p.Asp31Gly), gnomAD rs1342708327, REVEL 0.10, CADD 23.40
- D31Y (p.Asp31Tyr), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10028, Variant assessed as somatic; moderate impact.
- p.Asp29 Ala33del, gnomAD 1-32274270-GTTGGG, CADD 10.50
- D31D (p.Asp31Asp), rs772820417, gnomAD 1-32274284-T-C, CADD 9.65
- D31H (p.Asp31His), gnomAD 1-32274420-G-C, REVEL 0.07, CADD 24.40
- G32V (p.Gly32Val), gnomAD rs1218166453, REVEL 0.05, CADD 21.00
- G32G (p.Gly32Gly), rs1436048610, gnomAD 1-32274254-C-A, CADD 6.77
- G32R (p.Gly32Arg), gnomAD 1-32274273-G-A, CADD 6.86
- G32E (p.Gly32Glu), rs1283831307, gnomAD 1-32274292-G-A, CADD 8.18
- G32S (p.Gly32Ser), gnomAD 1-32274423-G-A, REVEL 0.03, CADD 18.10
- G32D (p.Gly32Asp), gnomAD 1-32274424-G-A, REVEL 0.06, CADD 19.90
- K33K (p.Lys33Lys), rs1029313140, gnomAD 1-32274428-G-A, CADD 12.30
- K33N (p.Lys33Asn), gnomAD 1-32274428-G-C, REVEL 0.01, CADD 20.90
- G34D (p.Gly34Asp), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10028, Ensembl rs1640192059, REVEL 0.09, CADD 7.91, Variant assessed as somatic; moderate impact.
- G34R (p.Gly34Arg), rs770282584, ClinGen CA740973, ClinVar RCV002298327, ExAC rs770282584, REVEL 0.08, CADD 13.80, Uncertain significance, Severe combined immunodeficiency due to LCK deficiency
- G34C (p.Gly34Cys), gnomAD 1-32274429-G-T, REVEL 0.11, CADD 17.30
- G34G (p.Gly34Gly), rs1349391809, gnomAD 1-32274431-C-A, CADD 11.90
- T35=, NCI-TCGA Cosmic COSV1002, NCI-TCGA Cosmic COSV6074, Variant assessed as somatic; low impact.
- T35M (p.Thr35Met), rs1640192230, ClinGen CA339635885, NCI-TCGA Cosmic COSV1002, cosmic curated COSV10028, REVEL 0.02, CADD 10.40, Uncertain significance, Severe combined immunodeficiency due to LCK deficiency
- L36R (p.Leu36Arg), ExAC rs755220816, gnomAD rs755220816, REVEL 0.18, CADD 16.10
- L36L (p.Leu36Leu), gnomAD 1-32274737-C-T, CADD 11.50
- L36M (p.Leu36Met), gnomAD 1-32274737-C-A, REVEL 0.03, CADD 12.00
- L36P (p.Leu36Pro), gnomAD 1-32274738-T-C, REVEL 0.17, CADD 18.20
- L37I (p.Leu37Ile), gnomAD 1-32274740-C-A, REVEL 0.02, CADD 6.02
- I38N (p.Ile38Asn), 1000Genomes rs564082487, ExAC rs564082487, gnomAD rs564082487, REVEL 0.14, CADD 15.00
- I38V (p.Ile38Val), gnomAD 1-32274743-A-G, REVEL 0.02, CADD 2.44
- I38I (p.Ile38Ile), gnomAD 1-32274745-C-T, CADD 0.21
- R39* (p.Arg39Ter), rs2521638529, ClinGen CA339635994, ClinVar RCV002903252, Pathogenic
- R39Q (p.Arg39Gln), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10028, Ensembl rs1640202238, REVEL 0.11, CADD 21.00, Variant assessed as somatic; moderate impact.
- R39G (p.Arg39Gly), rs758532596, gnomAD 1-32274225-A-G, CADD 13.20
- R39M (p.Arg39Met), rs1234158033, gnomAD 1-32274226-G-T, CADD 15.30
- R39L (p.Arg39Leu), gnomAD 1-32274747-G-T, REVEL 0.16, CADD 20.70
- N40S (p.Asn40Ser), rs752991931, ClinGen CA740988, ClinVar RCV002028260, ClinVar RCV005592364, REVEL 0.04, CADD 15.70, Uncertain significance, Severe combined immunodeficiency due to LCK deficiency; not specified
- N40N (p.Asn40Asn), gnomAD 1-32274751-T-C, CADD 8.71
- N40K (p.Asn40Lys), gnomAD 1-32274751-T-A, REVEL 0.02, CADD 13.80
- G41D (p.Gly41Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G41S (p.Gly41Ser), ExAC rs756491346, gnomAD rs756491346
- G41V (p.Gly41Val), gnomAD 1-32274325-G-T, CADD 22.90
- G41G (p.Gly41Gly), gnomAD 1-32274754-C-T, CADD 12.00
- S42A (p.Ser42Ala), gnomAD 1-32274300-T-G, CADD 13.50
- S42P (p.Ser42Pro), rs566487811, gnomAD 1-32274321-T-C, CADD 13.00
- S42C (p.Ser42Cys), gnomAD 1-32274756-C-G, REVEL 0.06, CADD 22.40
- E43D (p.Glu43Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E43G (p.Glu43Gly), TOPMed rs1254158000, gnomAD rs1254158000
- V44L (p.Val44Leu), cosmic curated COSV10028, ExAC rs778290248, TOPMed rs778290248, gnomAD rs778290248, REVEL 0.06, CADD 18.60
- R45Q (p.Arg45Gln), rs145088108, ClinGen CA740992, ClinVar RCV000547015, ClinVar RCV001675930, REVEL 0.09, CADD 22.10, Benign/Likely benign, not specified; Severe combined immunodeficiency due to LCK deficiency; not provi
- R45W (p.Arg45Trp), rs139649211, cosmic curated COSV60738, ESP rs139649211, ExAC rs139649211, REVEL 0.13, CADD 23.20, Variant assessed as somatic; moderate impact.
- R45G (p.Arg45Gly), gnomAD 1-32274827-A-G, CADD 7.64
- R45R (p.Arg45Arg), gnomAD 1-32274829-G-A, CADD 4.74
- D46E (p.Asp46Glu), Ensembl rs1640203012
- D46N (p.Asp46Asn), gnomAD 1-32274767-G-A, REVEL 0.07, CADD 22.80
- P47A (p.Pro47Ala), ExAC rs778252394, gnomAD rs778252394, REVEL 0.10, CADD 22.10
- P47L (p.Pro47Leu), TOPMed rs999073024
- P47S (p.Pro47Ser), gnomAD 1-32274318-C-T, CADD 5.97
- P47P (p.Pro47Pro), rs745339412, gnomAD 1-32274772-A-G, CADD 11.40
- L48V (p.Leu48Val), rs771590192, ClinGen CA740995, ClinVar RCV002632343, ClinVar RCV004069042, REVEL 0.10, CADD 18.20, Uncertain significance, Severe combined immunodeficiency due to LCK deficiency; not specified
- L48M (p.Leu48Met), gnomAD 1-32274773-C-A, REVEL 0.08, CADD 23.10
- L48L (p.Leu48Leu), rs771590192, gnomAD 1-32274773-C-T, CADD 12.30
- V49A (p.Val49Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- T50A (p.Thr50Ala), gnomAD 1-32274327-A-G, CADD 18.10
- T50T (p.Thr50Thr), gnomAD 1-32274329-C-T, CADD 20.40
- Y51C (p.Tyr51Cys), TOPMed rs1404547164, gnomAD rs1404547164, REVEL 0.14, CADD 22.60
- Y51F (p.Tyr51Phe), TOPMed rs1404547164, gnomAD rs1404547164, REVEL 0.11, CADD 17.70
- Y51Y (p.Tyr51Tyr), rs950834998, gnomAD 1-32274784-C-T, CADD 1.35
- E52D (p.Glu52Asp), rs373458731, ESP rs373458731, ExAC rs373458731, TOPMed rs373458731, REVEL 0.03, CADD 8.86, Variant assessed as somatic; moderate impact.
- E52K (p.Glu52Lys), NCI-TCGA Cosmic COSV6073, cosmic curated COSV60738, REVEL 0.13, CADD 20.50, Variant assessed as somatic; moderate impact.
- E52Q (p.Glu52Gln), rs2521639041, ClinGen CA339636118, ClinVar RCV002297700, Uncertain significance, Severe combined immunodeficiency due to LCK deficiency
- E52* (p.Glu52Ter), gnomAD 1-32274785-G-T, CADD 36.00
- G53S (p.Gly53Ser), gnomAD rs1443973811, REVEL 0.05, CADD 17.30
- G53R (p.Gly53Arg), gnomAD 1-32274788-G-C, REVEL 0.09, CADD 19.20
- S54A (p.Ser54Ala), rs540222297, ClinGen CA740997, ClinVar RCV001042876, 1000Genomes rs540222297, REVEL 0.05, CADD 8.93, Uncertain significance, Severe combined immunodeficiency due to LCK deficiency; not specified
- S54C (p.Ser54Cys), rs147431889, ClinGen CA740998, cosmic curated COSV10741, ClinVar RCV000652175, REVEL 0.03, CADD 11.60, Benign/Likely benign, not specified; Severe combined immunodeficiency due to LCK deficiency; not provi
- N55K (p.Asn55Lys), gnomAD rs1282058272
- N55S (p.Asn55Ser), ExAC rs776547244, gnomAD rs776547244, REVEL 0.02, CADD 4.28
- N55N (p.Asn55Asn), rs1282058272, gnomAD 1-32274796-T-C, CADD 5.32
- P56L (p.Pro56Leu), rs761633690, NCI-TCGA Cosmic COSV1002, cosmic curated COSV10028, ExAC rs761633690, REVEL 0.13, CADD 22.20, Variant assessed as somatic; moderate impact.
- P56T (p.Pro56Thr), gnomAD 1-32274797-C-A, REVEL 0.11, CADD 20.10
- P56R (p.Pro56Arg), gnomAD 1-32274798-C-G, REVEL 0.10, CADD 18.40
- P56P (p.Pro56Pro), rs765261247, gnomAD 1-32274799-G-A, CADD 1.80
- P57L (p.Pro57Leu), NCI-TCGA Cosmic COSV6074, cosmic curated COSV60742, REVEL 0.09, CADD 23.10, Variant assessed as somatic; moderate impact.
- P57S (p.Pro57Ser), gnomAD 1-32274800-C-T, REVEL 0.09, CADD 22.50
- P57P (p.Pro57Pro), rs528967735, gnomAD 1-32274802-G-A, CADD 2.21
- A58V (p.Ala58Val), rs568140101, ClinGen CA741003, ClinVar RCV002215416, ClinVar RCV004711775, REVEL 0.10, CADD 19.90, Likely benign, not provided; Severe combined immunodeficiency due to LCK deficiency
- A58T (p.Ala58Thr), gnomAD 1-32274279-G-A, CADD 8.59
- A58A (p.Ala58Ala), rs1640187948, gnomAD 1-32274281-A-G, CADD 9.99
- A58P (p.Ala58Pro), gnomAD 1-32274292-GA-G, CADD 8.40
- S59T (p.Ser59Thr), ESP rs151169932
- P60L (p.Pro60Leu), ExAC rs752903747, gnomAD rs752903747, REVEL 0.12, CADD 23.70
- P60S (p.Pro60Ser), gnomAD 1-32274809-C-T, REVEL 0.10, CADD 21.60
- P60P (p.Pro60Pro), rs756473344, gnomAD 1-32274811-A-C, CADD 8.39
- L61R (p.Leu61Arg), TOPMed rs1476466097, gnomAD rs1476466097, REVEL 0.10, CADD 22.80
- Q62E (p.Gln62Glu), ExAC rs764357331, gnomAD rs764357331, REVEL 0.06, CADD 16.80
Public LCK analysis runs
- LCK analysis run — LCK (701 variants) — completed 2026-08-19